Literature DB >> 11856743

Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells.

Margaret M Mc Gee1, Giuseppe Campiani, Anna Ramunno, Vito Nacci, Mark Lawler, D Clive Williams, Daniela M Zisterer.   

Abstract

The mitogen-activated protein (MAP) kinase family is activated in response to a wide variety of external stress signals such as UV irradiation, heat shock, and many chemotherapeutic drugs and leads to the induction of apoptosis. A novel series of pyrrolo-1,5-benzoxazepines have been shown to potently induce apoptosis in chronic myelogenous leukemia (CML) cells, which are resistant to many chemotherapeutic agents. In this study we have delineated part of the mechanism by which a representative compound known as PBOX-6 induces apoptosis. We have investigated whether PBOX-6 induces activation of MAP kinase signaling pathways in CML cells. Treatment of K562 cells with PBOX-6 resulted in the transient activation of two JNK isoforms, JNK1 and JNK2. In contrast, PBOX-6 did not activate the extracellular signal-regulated kinase (ERK) or p38. Apoptosis was found to occur independently of the small GTPases Ras, Rac, and Cdc42 but involved phosphorylation of the JNK substrates, c-Jun and ATF-2. Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6. Consistent with this finding, transfection of K562 cells with the JNK scaffold protein, JIP-1, inhibited JNK activity and apoptosis induced by PBOX-6. JIP-1 specifically scaffolds JNK, MKK7, and members of the mixed-lineage kinase (MLK) family, implicating these kinases upstream of JNK in the apoptotic pathway induced by PBOX-6 in K562 cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856743     DOI: 10.1074/jbc.M112058200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases.

Authors:  Anshuman Singh; Shubham Upadhayay; Sidharth Mehan
Journal:  Neurotox Res       Date:  2021-08-25       Impact factor: 3.911

2.  Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation.

Authors:  Ashwani Khurana; Chinmoy S Dey
Journal:  J Muscle Res Cell Motil       Date:  2005-02-24       Impact factor: 2.698

3.  A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin.

Authors:  Navin K Verma; Eugene Dempsey; Jennifer Conroy; Peter Olwell; Anthony M Mcelligott; Anthony M Davies; Dermot Kelleher; Stefania Butini; Giuseppe Campiani; D Clive Williams; Daniela M Zisterer; Mark Lawler; Yuri Volkov
Journal:  J Mol Med (Berl)       Date:  2008-02-13       Impact factor: 4.599

4.  Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells.

Authors:  Jennifer C Lennon; Stefania Butini; Giuseppe Campiani; Anne O'Meara; D Clive Williams; Daniela M Zisterer
Journal:  Invest New Drugs       Date:  2016-06-22       Impact factor: 3.850

5.  miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.

Authors:  Shatovisha Dey; Jason J Kwon; Sheng Liu; Gabriel A Hodge; Solaema Taleb; Teresa A Zimmers; Jun Wan; Janaiah Kota
Journal:  Mol Cancer Res       Date:  2019-10-29       Impact factor: 5.852

Review 6.  Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines.

Authors:  L M Greene; S Butini; G Campiani; D C Williams; D M Zisterer
Journal:  J Cancer       Date:  2016-12-04       Impact factor: 4.207

7.  Tanshinone I inhibited growth of human chronic myeloid leukemia cells via JNK/ERK mediated apoptotic pathways.

Authors:  Siya Sun; Lingyan Zhu; Mengru Lai; Rubin Cheng; Yuqing Ge
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.